USB|CAR-T: Using CRISPR 2.0 to Generate Universal SLAMF7/BCMA CAR-T Cells for Treating Multiple Myeloma

Funding Cycle:

2023-2024

Name:

Karl Petri

Type of Award:

Translational Research Award

Home Institution:

University Hospital Wurzburg

Description

The project focuses on developing a novel CAR-T cell therapy aimed at treating multiple myeloma by utilizing advanced gene editing technologies to engineer a universal CAR-T cell product targeting SLAMF7 and BCMA. The approach involves strategic gene modifications to enhance the therapy’s compatibility and effectiveness while minimizing immune rejection and reducing the risk of adverse reactions.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

See All of the Member Benefits

Become a Member Today